BofA/Merrill Lynch Downgrades Human Genome Sciences (HGSI) Two-Notches to Underperform
Tweet Send to a Friend
BofA/Merrill Lynch downgraded Human Genome Sciences (NASDAQ: HGSI) from Buy to Underperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
